Latest follicular lymphoma research updates from recent scientific conferences
The team updates from recent scientific conferences on the latest research in follicular lymphoma, from cutting-edge therapies to genetic insights.
What is the potential for minimal residual disease in follicular lymphoma treatment?
Minimal/measurable residual disease refers to the small number of cancer cells remaining in the body after treatment.
Immunotherapy: Can we make better CAR-Ts and bispecific antibodies?
How do we improve immunotherapy treatments to ensure long-lasting effectiveness, fewer side effects, and ensure they are accessible?
Immunotherapy: A breakthrough in follicular lymphoma treatment
Dr Mitchell Smith, FLF CMO, explains Immunotherapy and what it means for people living with follicular lymphoma in terms of treatment.
Latest breakthroughs & updates on FL, from ASH 2023 Annual Meeting
Dr Mitchell Smith, FLF CMO, reports on the most exciting presentations at ASH 2023 including fundamental scientific discoveries and ongoing clinic trials.
Exciting insights about follicular lymphoma at 17-ICML
This article presents key insights from the conference, shedding light on exciting developments in the field. The knowledge and insights we gained left us inspired and energised.
Highlights from our satellite symposium
At the 17th International Conference on Malignant Lymphoma (17-ICML), the FLF hosted their own symposium: “What Will it Take to Cure FL?”. Read more to find out the key takeaways and highlights from the symposium.
Dr Mitchell Smith on Future Directions in FL
Dr Mitchell Smith on Future Directions in FL Dr Mitchell Smith, CMO at the FLF, shares his insights in what the future holds for follicular lymphoma research. In his article, he outlines the key questions in follicular lymphoma, and lays out which areas of research look to be most promising in leading us to better […]
ASH Annual Meeting 2022 – Research and insight summary
ASH Annual Meeting 2022 – summary and key take-outs By Dr Zoe Drymoussi During the 9-12th December 2022, the FLF team attended, in person, for the biggest events of the year in the world of haematology – the American Society of Hematology (ASH) annual meeting. More than 25,000 delegates, showcasing 3000+ abstracts, took over the […]
Looking back over the last 25 years for FL – the Rituximab era
Looking back over the last 25 years for FL – the Rituximab era By Dr Mitchell Smith, Chief Medical Officer A recent re-publication marking 25 years since the seminal 1998 Journal of Clinical Oncology paper (1) upon which Rituximab was approved for relapsed/refractory follicular or low-grade lymphoma (1997 by U.S. FDA, and 1998 by European […]